STOK logo

Stoke Therapeutics, Inc. (STOK) EBITDA

Annual EBITDA:

-$99.19M+$13.11M(+11.67%)
December 31, 2024

Summary

  • As of today, STOK annual EBITDA is -$99.19 million, with the most recent change of +$13.11 million (+11.67%) on December 31, 2024.
  • During the last 3 years, STOK annual EBITDA has fallen by -$14.10 million (-16.58%).
  • STOK annual EBITDA is now -1723.10% below its all-time high of -$5.44 million, reached on December 31, 2017.

Performance

STOK EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherSTOKincome statement metrics

Quarterly EBITDA:

-$42.10M-$15.86M(-60.44%)
September 30, 2025

Summary

  • As of today, STOK quarterly EBITDA is -$42.10 million, with the most recent change of -$15.86 million (-60.44%) on September 30, 2025.
  • Over the past year, STOK quarterly EBITDA has dropped by -$13.21 million (-45.72%).
  • STOK quarterly EBITDA is now -137.49% below its all-time high of $112.32 million, reached on March 31, 2025.

Performance

STOK Quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherSTOKincome statement metrics

TTM EBITDA:

$31.43M-$13.21M(-29.59%)
September 30, 2025

Summary

  • As of today, STOK TTM EBITDA is $31.43 million, with the most recent change of -$13.21 million (-29.59%) on September 30, 2025.
  • Over the past year, STOK TTM EBITDA has increased by +$144.18 million (+127.87%).
  • STOK TTM EBITDA is now -29.59% below its all-time high of $44.64 million, reached on June 30, 2025.

Performance

STOK TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherSTOKincome statement metrics

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

STOK EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1Y1 Year+11.7%-45.7%+127.9%
3Y3 Years-16.6%-60.5%+131.8%
5Y5 Years-181.6%-218.6%+165.2%

STOK EBITDA Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs LowTTM vs HighTTM vs HighTTM vs LowTTM vs Low
3Y3-Year-16.6%+11.7%-137.5%at low-29.6%+127.6%
5Y5-Year-181.6%+11.7%-137.5%at low-29.6%+127.6%
All-TimeAll-Time-1723.1%+11.7%-137.5%at low-29.6%+127.6%

STOK EBITDA History

DateAnnualQuarterlyTTM
Sep 2025
-
-$42.10M(-60.4%)
$31.43M(-29.6%)
Jun 2025
-
-$26.24M(-123.4%)
$44.64M(+4.7%)
Mar 2025
-
$112.32M(+995.2%)
$42.65M(+144.0%)
Dec 2024
-$99.19M(+11.7%)
-$12.55M(+56.6%)
-$96.93M(+14.0%)
Sep 2024
-
-$28.89M(-2.3%)
-$112.75M(-2.6%)
Jun 2024
-
-$28.23M(-3.6%)
-$109.90M(+3.4%)
Mar 2024
-
-$27.26M(+3.9%)
-$113.76M(-3.4%)
Dec 2023
-$112.30M(-9.2%)
-$28.37M(-9.0%)
-$110.04M(-2.2%)
Sep 2023
-
-$26.03M(+18.9%)
-$107.69M(+0.2%)
Jun 2023
-
-$32.09M(-36.3%)
-$107.89M(-7.7%)
Mar 2023
-
-$23.54M(+9.5%)
-$100.19M(+0.6%)
Dec 2022
-$102.81M(-20.8%)
-$26.02M(+0.8%)
-$100.82M(-2.1%)
Sep 2022
-
-$26.22M(-7.5%)
-$98.70M(-4.4%)
Jun 2022
-
-$24.40M(-1.0%)
-$94.59M(-3.2%)
Mar 2022
-
-$24.17M(-1.1%)
-$91.69M(-9.4%)
DateAnnualQuarterlyTTM
Dec 2021
-$85.09M(-63.1%)
-$23.91M(-8.1%)
-$83.83M(-13.3%)
Sep 2021
-
-$22.11M(-2.8%)
-$74.01M(-13.7%)
Jun 2021
-
-$21.50M(-31.8%)
-$65.12M(-16.0%)
Mar 2021
-
-$16.32M(-15.9%)
-$56.15M(-9.3%)
Dec 2020
-$52.16M(-48.1%)
-$14.08M(-6.6%)
-$51.37M(-6.5%)
Sep 2020
-
-$13.21M(-5.5%)
-$48.22M(-7.8%)
Jun 2020
-
-$12.53M(-8.6%)
-$44.72M(-10.3%)
Mar 2020
-
-$11.54M(-5.6%)
-$40.53M(-15.0%)
Dec 2019
-$35.23M(-180.3%)
-$10.93M(-12.5%)
-$35.23M(-45.0%)
Sep 2019
-
-$9.72M(-16.5%)
-$24.30M(-66.6%)
Jun 2019
-
-$8.34M(-33.6%)
-$14.58M(-133.6%)
Mar 2019
-
-$6.24M(-232.0%)
-$6.24M(-232.0%)
Dec 2018
-$12.57M(-131.0%)
-
-
Mar 2018
-
-$1.88M
-$1.88M
Dec 2017
-$5.44M
-
-

FAQ

  • What is Stoke Therapeutics, Inc. annual EBITDA?
  • What is the all-time high annual EBITDA for Stoke Therapeutics, Inc.?
  • What is Stoke Therapeutics, Inc. annual EBITDA year-on-year change?
  • What is Stoke Therapeutics, Inc. quarterly EBITDA?
  • What is the all-time high quarterly EBITDA for Stoke Therapeutics, Inc.?
  • What is Stoke Therapeutics, Inc. quarterly EBITDA year-on-year change?
  • What is Stoke Therapeutics, Inc. TTM EBITDA?
  • What is the all-time high TTM EBITDA for Stoke Therapeutics, Inc.?
  • What is Stoke Therapeutics, Inc. TTM EBITDA year-on-year change?

What is Stoke Therapeutics, Inc. annual EBITDA?

The current annual EBITDA of STOK is -$99.19M

What is the all-time high annual EBITDA for Stoke Therapeutics, Inc.?

Stoke Therapeutics, Inc. all-time high annual EBITDA is -$5.44M

What is Stoke Therapeutics, Inc. annual EBITDA year-on-year change?

Over the past year, STOK annual EBITDA has changed by +$13.11M (+11.67%)

What is Stoke Therapeutics, Inc. quarterly EBITDA?

The current quarterly EBITDA of STOK is -$42.10M

What is the all-time high quarterly EBITDA for Stoke Therapeutics, Inc.?

Stoke Therapeutics, Inc. all-time high quarterly EBITDA is $112.32M

What is Stoke Therapeutics, Inc. quarterly EBITDA year-on-year change?

Over the past year, STOK quarterly EBITDA has changed by -$13.21M (-45.72%)

What is Stoke Therapeutics, Inc. TTM EBITDA?

The current TTM EBITDA of STOK is $31.43M

What is the all-time high TTM EBITDA for Stoke Therapeutics, Inc.?

Stoke Therapeutics, Inc. all-time high TTM EBITDA is $44.64M

What is Stoke Therapeutics, Inc. TTM EBITDA year-on-year change?

Over the past year, STOK TTM EBITDA has changed by +$144.18M (+127.87%)
On this page